LondonTwo COVID drugs cut clotting risk by more than half.
A 2,524-patient study found remdesivir and tocilizumab each linked to lower thrombosis odds beyond standard blood thinners, using trial-emulation methods since no randomized trial was run.
The benefit faded over time, leaving the drugs’ longer-term effect untested.
Sources: Nature